Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02085135 · ClinicalTrials.gov registry record · Phase 3

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

A Phase 3 study, sponsored by Alkermes.

Completed
Registry status
Phase 3
Development phase
66
Enrollment target

NCT02085135 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02085135, a Phase 3 study, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 3
Development phase
66 participants
Enrollment target

Study Summary

This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.

Interventions

  • DRUG ALKS 5461

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2014-02
Est. Completion 2014-09
Phase Phase 3

Sponsor

Alkermes

66 total trials

What the Registry Record Tells You About NCT02085135

The ClinicalTrials.gov registry entry for NCT02085135 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ALKS 5461 is the first listed.

NCT02085135 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02085135 about?

NCT02085135 is a clinical study titled "A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)". This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.

What is the current status of trial NCT02085135?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 66 participants. The study started on 2014-02. Estimated completion is 2014-09.

What interventions are being tested in trial NCT02085135?

The interventions under investigation include: ALKS 5461 (DRUG).

Who is sponsoring clinical trial NCT02085135?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.